Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linerixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis
NCT04950127Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of linerixibat in cholestatic pruritus, sponsored by GSK. Started Aug 2021; status: completed.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on NCT04950127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950127.